(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows - 2Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- 3Landslides triggered by heavy rainfall kill at least 20 people in Tanzania
- 4Flu cases are spiking earlier than usual. What you need to know.
- 5Israel says it killed armed Hamas 'terrorists' in Gaza
- I watched more than 500 new movies this year. These are the 25 best ones.
- Make your choice for the PS5 game that you love playing with companions!
- One of the best meteor showers of the year peaks at the worst possible time this week
- Select Your Cherished Fish
- 4 astronauts are en route home from ISS after medical issue forces early exit
- Am I a Summer, or is this a scam? What I learned from color analysis.
- New 'People We Meet on Vacation' trailer teases Poppy and Alex romance: Everything we know about the new Netflix movie
- German mid-sized firms gloomy on outlook, survey finds
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
